Literature DB >> 3144694

Preferential and novel activation of H-ras in human bladder carcinomas.

K V Visvanathan1, R D Pocock, I C Summerhayes.   

Abstract

In a survey of primary human bladder carcinomas from 24 patients, using the NIH/3T3 transfection nude mouse tumor assay, we have detected an activated c-H-ras-1 gene in four cases. Two of these scored negative in primary transfections using a NIH/3T3 focus assay. Oligonucleotide analysis of genomic and enzymatically amplified DNA revealed substitution of valine at codon 12 in DNA from three transfectants and their parental carcinomas, which was absent from the DNA of normal tissue of each of these patients. The fourth activation was identified as a cysteine substitution at codon 13, a novel activation of c-H-ras-1 in a solid tumor sample. Thus, all seven activated ras genes reported in human urothelial tumors (Fujita et al., Proc. Natl. Acad. Sci. USA 82, 3849-3853, 1985) have been c-H-ras-1 genes, strongly suggesting that this member of the ras gene family is preferentially activated in cells of transitional origin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144694

Source DB:  PubMed          Journal:  Oncogene Res        ISSN: 0890-6467


  16 in total

Review 1.  The pervasiveness of macropinocytosis in oncological malignancies.

Authors:  Cosimo Commisso
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

Review 2.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

3.  Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants.

Authors:  Abdallah Sayyed-Ahmad; Priyanka Prakash; Alemayehu A Gorfe
Journal:  Proteins       Date:  2017-05-31

Review 4.  Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.

Authors:  C Cordon-Cardo; J Sheinfeld
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  Ubiquitin on ras: warden or partner in crime?

Authors:  Cathie M Pfleger
Journal:  Sci Signal       Date:  2011-03-08       Impact factor: 8.192

6.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

Review 7.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

8.  K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.

Authors:  T Enomoto; C M Weghorst; M Inoue; O Tanizawa; J M Rice
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

9.  Short-term culture of exfoliated cells from the urine of patients with bladder tumors.

Authors:  F Herz; D Deitch; S A Adler; D Brijlall
Journal:  Urol Res       Date:  1993-01

10.  Ras oncogene point mutations in bladder cancer resistant to cisplatin.

Authors:  D P Wood; A E Anderson; R Fair; R S Chaganti
Journal:  Urol Res       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.